The SHINE Group research focus on aberrations in the vascular compartment in patients with acute critical illness resulting in shock induced endotheliopathy (SHINE) with multiorgan failure and strategies to mitigate this dreaded complication based on metabolic systems analysis.
Within transfusion medicine we focus on patients with severe/complex bleedings and how to goal-direct haemostatic resuscitation to the individual patient’s whole blood haemostatic phenotype, an approach entitled the “Copenhagen Concept”.
Another important research focus concerns how to improve the biological compatibility between the blood donor and the transfused patient using network analysis applied to the human protein-protein interactome and coupled to “big” data from registries.
2013-2019 FP7-HEALTH-2013-INNOVATION-1-602771 TACTIC
2018-2023 Innovation Fund Denmark ”Grand Solutions” COMBAT-SHINE
2018-2022 Independent Research Fund Denmark COMBAT-SHINE
2019-2022 Novo Nordisk Foundation Investigator Trials SHINE-TRAUMA
2019-2022 Danish Regions “Medicinpuljen” SHINE-TRAUMA
2019-2022 Rigshospitalet´s 3-year grant – METABO SHINE-TRAUMA